title: American Society of Clinical Oncology--42nd annual meeting. Poster presentations on leukemia and cytotoxic chemotherapy. 2-6 June 2006, Atlanta, GA, USA.
authors.affiliation: Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. john.cleverley@thomson.com
authors.forename: John
authors.initials: J
authors.lastname: Cleverley
mesh_terms: D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000031:analogs & derivatives / Q000494:pharmacology; D004338:Drug Combinations; D006072:Gossypol / Q000494:pharmacology; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D034721:Mastocytosis, Systemic / Q000188:drug therapy; D015394:Molecular Structure; D011743:Pyrimidines / Q000494:pharmacology; D011759:Pyrrolidines; D013873:Thionucleotides / Q000494:pharmacology; D013941:Thymine; D014271:Trifluridine / Q000494:pharmacology; D014498:Uracil / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: C497722:4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1H)-pyrimidinone; D004338:Drug Combinations; D011743:Pyrimidines; D011759:Pyrrolidines; D013873:Thionucleotides; C000613803:trifluridine tipiracil drug combination; D003561:Cytarabine; D014498:Uracil; C408162:oblimersen; C498826:nilotinib; D006072:Gossypol; D013941:Thymine; D014271:Trifluridine